109 results
DEFA14A
PVCT
Provectus Biopharmaceuticals, Inc.
20 Jun 24
Additional proxy soliciting materials
6:03am
outcomes or statements regarding an outlook.
The safety and efficacy of the agents and/or uses under investigation have not been established
8-K
EX-99.1
PVCT
Provectus Biopharmaceuticals, Inc.
16 Apr 24
Provectus Biopharmaceuticals Announces Management Additions and Reiterates Commitment to Shareholder Value Creation
4:58pm
,” “should,” “believe,” and similar words suggesting future outcomes or statements regarding an outlook.
The safety and efficacy of the agents and/or uses
8-K
EX-99.1
PVCT
Provectus Biopharmaceuticals, Inc.
27 Mar 24
Entry into a Material Definitive Agreement
12:10pm
testing, pilot in vivo safety and clinical studies, and the scrutiny that comes with numerous peer-reviewed publications and medical conference … outcomes or statements regarding an outlook.
The safety and efficacy of the agents and/or uses under investigation have not been established
8-K
EX-99.1
mcxrlychsvxy a5t
15 Feb 24
Provectus Biopharmaceuticals Announces First Quarter 2024 Conference Call
8:05am
8-K
EX-99.1
pn8vr68d5md2mtx dkr
12 Dec 22
Other Events
8:00am
DEFA14A
fdb cponrf
26 May 22
Additional proxy soliciting materials
1:26pm
DEFA14A
e09hszew83rz
19 May 22
Additional proxy soliciting materials
6:15am
8-K
EX-99.1
04ny qxkry3bm1a9jojj
19 Apr 22
Other Events
4:31pm